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Abstract 
Background. A high frequency of venous thromboembolism (VTE) has been observed after lung, kidney, and liver 
transplantation. However, data about the incidence of this complication among heart transplant (HT) recipients are 
lacking. 
Methods. We analyzed the incidence, recurrence, and predisposing factors of VTE in a single-center cohort of 635 
patients who underwent HT from April 1991 to April 2013. Deep venous thrombosis (DVT) and pulmonary 
embolism (PE) were considered as VTE episodes. 
Results. During a median post-transplant follow-up of 8.4 years, 62 VTE episodes occurred in 54 patients (8.5%). 
Incidence rates of VTE, DVT, and PE were, respectively, 12.7 (95% confidence interval [CI], 9.7–16.3), 8.4 (95% 
CI, 6.0–11.4), and 7.0 (95% CI 4.8–9.7) episodes per 1,000 patient-years. Incidence rates of VTE during the first 
post-transplant year and beyond were, respectively, 45.1 (95% CI, 28.9–67.1) and 8.7 (95% CI 6.2–11.2) episodes per 
1,000 patient-years. The incidence rate of VTE recurrence after a first VTE episode was 30.5 (95% CI, 13.2–60.2) 
episodes per 1,000 patient-years. By means of multivariable Cox regression, chronic renal dysfunction, older age, 
obesity, and the use of mammalian target of rapamycin inhibitors were identified as independent risk factors for VTE 
among HT recipients. 
Conclusions. VTE is a frequent complication after HT, mainly during the first post-operative year. In view of a high 
recurrence rate, long-term anti-coagulation should be considered in HT recipients who experience a first VTE 
episode. 
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Heart transplantation (HT) improves quality of life and survival in carefully selected patients with 
refractory heart failure.
1
 However, the life expectancy of HT recipients may be compromised by graft-
related complications, such as rejection and coronary allograft vasculopathy, as well as by comorbidities 
related to chronic immunosuppressive therapy, including infection, malignancy, diabetes mellitus, or 
renal dysfunction.
2
 Venous thromboembolism (VTE) is a less frequent but also relevant complication in 
some of these patients. 
 
Solid-organ transplant recipients are exposed to an increased risk of VTE.
3-14
 In 2 large population-




 the estimated incidence rates of VTE among 
individuals from the general population were, respectively, 1.33 and 1.22 cases per 1,000 persons-years, 
decreasing to 1.07 cases per 1,000 persons-years when cancer-related VTE episodes were excluded.
15
 
With variable follow-up duration among studies, the reported cumulative incidence of VTE varied 
between 4.5% and 9.1% in kidney transplant recipients,
3-6
 between 8.6% and 29% in lung transplant 
recipients,
7-10
 and between 0.4% and 4.6 % in liver transplant recipients.
11-13 
Although comparing data 
from such heterogeneous studies is difficult, previous literature suggests that VTE is significantly more 
frequent in solid organ recipients than in individuals from the general population. 
 
Major surgery, major trauma, prolonged bed rest, malignancy, obesity, renal dysfunction, 
thrombophilia, hormone replacement therapy, oral contraception, older age, and previous venous 
thromboembolism are consistent risk factors for VTE.
17 
 
To the best of our knowledge, only one published original paper
14
 has addressed the occurrence of 
VTE after HT. The authors of that study
14
 focused specifically on the role of sirolimus, a mammalian 
target of rapamycin (mTOR) inhibitor, as a risk factor for VTE. The purpose of our study was to describe 
the cumulative incidence and recurrence risk of VTE in HT recipients and to identify predisposing 
factors. 
Methods 
The Complejo Hospitalario Universitario A Coruña Institutional Review Board approved the study 
protocol. 
Setting and design of the study 
We conducted an observational study based on the historical cohort of patients aged ≥18 years who 
underwent HT at the Complejo Hospitalario Universitario A Coruña (A Coruña, Spain) from April 1, 
1991, to April 30, 2013. Our institution is a tertiary care university medical center with a reference 
population of ~2.7 million individuals and a routine activity of ~25 HT per year. Data for the study were 
extracted from a prospective database in which extensive clinical information has been recorded about all 
HT procedures performed at our institution since the beginning of our HT program in April 1, 1991. 
Follow-up protocol 
Patients were treated and monitored according to local protocols. During the early postoperative 
period, induction therapy with muromonab-CD3 or basiliximab was administered. The maintenance 
immunosuppressive regimen consisted of a combination of steroids, a calcineurin inhibitor (tacrolimus or 
cyclosporine A), and an anti-proliferative agent (azathioprine or mycophenolate mofetil). After the first 
post-transplant year, substitution of the anti-proliferative agent by an mTOR inhibitor (everolimus or 
sirolimus) was considered in selected patients with coronary allograft vasculopathy or recurrent 
cytomegalovirus infection. The introduction of an mTOR inhibitor was also considered in selected 
patients with malignancies or chronic renal dysfunction to minimize the exposure to calcineurin 
inhibitors. 
  
In our HT program, target serum levels of immunosuppressive drugs are 250 to 350 ng/ml (<6 months 
after HT), 150 to 250 ng/ml (6–12 months after HT), and 70 to 150 ng/ml (>1 year after HT) for 
cyclosporine A; 10 to 15 ng/ml (<1 year after HT) and 5 to 10 ng/ml (>1 year after HT) for tacrolimus; 3 
to 8 ng/ml for everolimus and 6 to 15 ng/ml for sirolimus. Our institution first used mycophenolate 
mofetil in September 1997, sirolimus in February 1999, basiliximab in February 2001, and everolimus in 
March 2005. 
 
Routine surveillance endomyocardial biopsies were performed periodically during the first 12 months 
after HT and afterwards only if rejection was clinically suspected. In stable patients, clinical visits, 
laboratory tests, 12-lead electrocardiogram, and transthoracic echocardiography were performed every 3 
to 6 months after the first post-transplant year. Coronary angiographies were performed in case of clinical 
suspicion of coronary allograft vasculopathy, and, since 2003, also in all asymptomatic patients, barring 
contraindications, at 1 month, 1 year, and every 5 years after HT. 
 
Thromboprophylaxis with sub-cutaneous low-molecular-weight heparins was recommended during 
hospital admissions in patients who required prolonged bed rest (>24 hours), according to evolving 
practices guidelines.
18
 Specific regimens used in our institution included enoxaparin sodium (Clexane; 
Sanofi Aventis, Bridgewater, NJ), 2,000 to 4,000 IU daily; bemiparin sodium (Hibor; Laboratorios 
Farmacéuticos ROVI, S.A, Madrid, Spain) 2,500 to 3,500 IU daily, and nadroparin calcium (Fraxiparina; 
GlaxoSmithKline, Brentford, United Kingdom), 2,850 to 5,700 IU daily. 
Data collection and definition of variables 
The raw data extracted for the present analysis included variables regarding demographics (age, 
gender), pre-transplant clinical history (underlying disease leading to HT, cardiovascular risk factors, 
chronic renal dysfunction, supportive therapies), HT surgery (combined or redo transplantation, donor 
characteristics, surgical times, emergency transplantation), baseline immunosuppression, and post-
transplant comorbidities (coronary allograft vasculopathy, malignancies). Chronic renal dysfunction was 
defined as the presence of a serum creatinine level >2 mg/dl at least for 3 months before HT. The term 
“emergency HT” refers to the highest level of waiting list priority (“status 0”), according to the criteria of 
the organ donor allocation system in Spain,
19
 which requires the presence of refractory heart failure 
depending on mechanical circulatory support or intravenous inotropes, together with mechanical 
ventilation, or complicated with refractory recurrent ventricular arrhythmia. 
 
Isolated deep venous thrombosis (DVT), isolated pulmonary embolism (PE), and simultaneous DVT 
plus PE were considered as VTE episodes. DVT was diagnosed by means of venous phlebography, 
venous echo Doppler, or computed tomography (CT) venography. PE was diagnosed by means of CT 
pulmonary angiogram, ventilation-perfusion nuclear scan, or autopsy. Complementary tests were driven 
by clinical findings and performed at the discretion of the attending physician, who was also responsible 
for determining the duration of oral anti-coagulation according to evolving practice guidelines.
17
 No 
specific diagnostic strategy was undertaken to identify silent VTE episodes in asymptomatic patients. 
Recurrence of VTE was defined as a new VTE episode occurring in a same patient at least 30 days after a 
previous one. 
 
To investigate the occurrence of VTE episodes, study follow-up was extended from the date of 
transplantation until August 31, 2013, or until the date of death in the case of patients who died. 
Statistical analysis 
Categoric variables are presented as proportions, and continuous variables are presented as mean ± 
standard deviation or median and interquartile range (IQR), depending on whether they were normally 
distributed. Clinical characteristics of patients who did and did not develop VTE after HT were compared 
by means of the chi-square test in the case of categoric variables and by the Student’s t-student test in the 
case of continuous ones. 
  
Independent risk factors for VTE were assessed by means of backward stepwise Cox proportional 
hazards regression models. Because the incidence density rates of VTE during the first post-transplant 
year and after the first post-transplant year were markedly different, we designed specific multivariable 
models for each of these periods. Candidate variables that entered multivariable backward stepwise 
analyses were those that showed a univariable association with the study outcome with a p-value <0.10. 
All statistical comparisons were 2-tailed, and statistical significance was set as a p-value <0.05. Statistical 
analysis was performed with SPSS Statistics 20 software (IBM Corp., Armonk, NY). 
Results 
Study population 
From April 1, 1991, to April 30, 2013, 635 patients, 107 (17%) of whom were women, aged ≥18 years 
underwent HT at our institution. Mean age was 54.6 ± 12.4 years. Transplantation was performed under a 
high-emergency status in 137 patients (22%), 102 (16%) of whom were on mechanical circulatory 
support and 81 (13%) of whom were on mechanical ventilation. 
 
Induction therapy was administered to 596 patients (94%). Initial maintenance immunosuppression 
included steroids in 624 (98%), tacrolimus in 98 (15%), cyclosporine A in 489 (77%), mycophenolate 
mofetil in 335 (53%), azathioprine in 240 (38%), sirolimus in 10 (2%), and everolimus in 7 (1%). 
 
After HT, 122 patients (20%) presented with malignancy, and 83 (13%) had a diagnosis of coronary 
allograft vasculopathy. An mTOR inhibitor was initiated in 187 patients (29%). Sirolimus was used in 59 
(9%), and everolimus in 128 (20%). 
VTE episodes 
During a median post-transplant follow-up of 8.4 years (IQR, 3.3–13.2 years), 54 patients (8.5%) 
experienced 62 VTE episodes. There were 28 isolated DVTs, 21 isolated PEs, and 13 instances of 
simultaneous DVT plus PE. Median time elapsed from HT to VTE was 2.6 years (IQR, 0.1–9 years). 
 
The DVT diagnosis was established by means of venous phlebography in 22 cases, by means of echo 
Doppler in 15, and by CT venography in 4. Localizations of DVT were the lower limbs in 37, the inferior 
vena cava in 2, the right upper limb in 1, and the cavernous bodies in 1. PE was diagnosed by means of 
CT pulmonary angiogram in 9 patients, by ventilation-perfusion nuclear scan in 20, and by autopsy in 5. 
 
Thirty VTE episodes (48%) occurred within the first 30 days after a hospital admission. Reasons for 
hospitalization were HT in 11, endomyocardial biopsies in 4; 2 hospitalizations each for pancreatitis, 
respiratory infection, and heart failure; and 1 hospitalization each because of mediastinal infection, 
urinary tract infection, infectious colitis, carcinomatosis, acute coronary syndrome, coronary bypass 
grafting, inguinal hernia surgery, abdominal aneurysm surgery, and thoracic trauma. 
 
Hospitalization involved prolonged (>24 hours) bed rest in 25 patients; 18 of these patients (72%) 
received evidence-based thromboprophylaxis. The remaining 32 VTE episodes (52%) occurred in 
ambulatory patients with no previous hospitalization, and only 3 (9%) were receiving evidence-based 
thromboprophylaxis at the time of VTE. 
Incidence of VTE 
The overall incidence rate of VTE in the study population was 12.7 (95% confidence interval [CI], 
9.7–16.3) episodes per 1,000 patient-years. Separated incidence rates of DVT and PE were, respectively, 
8.4 (95% CI 6.0–11.4) and 7.0 (95% CI 4.8–9.7) episodes per 1,000 patient-years. 
  
During the first post-transplant year, 24 VTE episodes occurred in 22 patients (3.8%), and after this, 
38 VTE episodes were diagnosed in 35 patients (6.5%). Incidence rates of VTE during the first post-
transplant year and after the first post-transplant year were, respectively, 45.1 (95% CI 28.9-67.1) and 8.7 
(95% CI 6.2-11.2) episodes per 1000 patient-years. Figure 1 shows the Kaplan-Meier estimates of the 




Figure 1. Kaplan-Meier estimates of the cumulative incidence of venous 
thromboembolism in the study population: (A) overall post-transplant follow-
up and (B) 1-year post-transplant follow-up. 
Clinical characteristics of patients with or without VTE 
Table 1 reports the pre-transplant and post-transplant clinical cha racteristics of patients who did and 
did not present with a VTE episode. At the time of HT, VTE patients were older and had a higher 
prevalence of chronic renal dysfunction (serum creatinine ≥2 mg/dl) and obesity (body mass index ≥ 30 
kg/m
2
). After HT, malignancies and the use of mTOR inhibitors were more frequent among patients who 
developed VTE. 
  
Table 1. Clinical Characteristics of Patients With or Without Venous Thromboembolism 
Variablesa 
VTE patients  Other patients 
p-value 
(n = 54)  (n = 581) 
     




 Age, years 58.3 ± 9  54.3 ± 12 0.003 
 Women 6 (11)  101 (17) 0.239 





  Ischemic heart disease 29 (54)  230 (40) 
 
  Dilated cardiomyopathy 18 (31)  225 (39) 
 
  Other 7 (15)  134 (21) 
 
Diabetes 7 (13)  87 (15) 0.691 
Hypertension 28 (52)  247 (43) 0.185 
Hypercholesterolemia 7 (13)  115 (20) 0.223 
Obesityb 14 (26)  77 (13) 0.011 
History of cigarette smoking 28 (52)  257 (51) 0.918 
Chronic renal dysfunctionc 9 (17)  49 (8) 0.045 
Mechanical ventilation 7 (13)  74 (13) 0.96 
Mechanical circulatory support 10 (18)  91 (16) 0.583 




 Second heart transplantation 0  9 (2) 0.357 
 Combined transplantation 1 (2)  23 (4) 0.44 
 Emergency transplantation 11 (20)  126 (22) 0.82 
 Female donor 6 (11)  101 (17) 0.239 
 Bypass time, min 123 ± 30  126 ± 48 0.488 
 Cold ischemic time, min 163 ± 80  190 ± 77 0.015 




 Induction therapy 53 (98)  542 (93) 0.144 
 Steroids 53 (98)  571 (98) 0.944 
 Cyclosporine 45 (83)  434 (75) 0.159 
 Tacrolimus 8 (15)  90 (15) 0.895 
 Mycophenolate mofetil 21 (39)  314 (54) 0.033 
 Azathioprine 31 (57)  209 (36) 0.002 
 Sirolimus 2 (4)  8 (1) 0.189 





 Coronary allograft vasculopathy 13 (19)  73 (13) 0.214 
 Malignancy 21 (39)  108 (18) <0.001 
 Switch to an mTOR inhibitord 30 (56)  157 (27) <0.001 
     
 
mTOR, mammalian target of rapamycin; VTE, venous thromboembolism. 
a Continuous data are shown as the mean ± standard deviation and categoric data as number (%). 
b Body mass index ≥30 kg/m2. 
c Serum creatinine ≥2 mg/dL. 
d Sirolimus or everolimus. 
Risk factors for VTE 
Multivariable Cox proportional hazards regression showed a statistically significant association 
between older age, chronic renal dysfunction, obesity, and the use of mTOR inhibitors with increased risk 
of VTE (Table 2). Post-transplant malignancy was associated with an increased risk of VTE in 
univariable analysis, but the statistical significance of this association was lost after multivariable 
adjustment. 
  
Table 2. Risk Factors for Venous Thromboembolism: Univariable And Multivariable Cox Proportional Hazards Regression 
Analysisa 
Variables 
Hazard ratio (95% confidence interval) 
Unadjusted p-value Adjusted p-value 
     
Overall follow-up 
    
 Age, years 1.04 (1.01–1.07) 0.012 1.04 (1.01–1.08) 0.017 
 Obesityb 2.30 (1.25–4.24) 0.007 1.88 (1.001–3.52) 0.050 
 Chronic renal dysfunctionc 2.20 (1.07–4.49) 0.031 2.06 (1.01–4.23) 0.048 
 Use of an mTOR inhibitord 2.08 (1.21–3.59) 0.008 1.87 (1.07–3.27) 0.029 
 Post-transplant malignancy 1.81 (1.04–3.52) 0.035 1.49 (0.84–2.61) 0.179 
<1 year after transplantation 
    
 Age (years) 1.11 (1.03–1.18) 0.003 1.12 (1.05–1.20) 0.001 
 Obesityb 2.81 (1.15–6.90) 0.024 2.71 (1.09–6.73) 0.032 
 Chronic renal dysfunctionc 3.12 (1.15–8.45) 0.025 2.83 (1.03–7.77) 0.043 
 Emergency transplantation 3.52 (1.52–8.13) 0.003 5.49 (2.35–12.83) <0.001 
>1 year after transplantation 
    
 Obesityb 2.02 (0.92–4.46) 0.081 1.64 (0.74–3.66) 0.226 
 Use of an mTOR inhibitord 2.73 (1.34–5.59) 0.006 2.56 (1.24–5.29) 0.011 
     
 
mTOR, mammalian target of rapamycin. 
a Variables shown in the Table are those that presented a univariable association with the study outcome with a p-value of <0.10. 
b Body mass index ≥ 30 kg/m2. 
c Serum creatinine ≥ 2 mg/dl. 
d Sirolimus or everolimus. 
Together with emergency HT, older age, chronic renal dysfunction, and obesity were identified as 
independent risk factors for VTE during the first post-transplant year, whereas the use of mTOR 
inhibitors was the unique variable that showed a statistically significant association with the occurrence of 
VTE after the first post-transplant year. 
 
The incidence rate per 1,000 patient-years of VTE after the initiation of an mTOR inhibitor was 21.1 
(95% CI, 12.3–33.7) episodes, with a rate of 19.4 (95% CI, 7.8–40.1) episodes in patients taking 
sirolimus, and 22.4 (95% CI, 10.7–41.1) episodes in patients taking everolimus. The median time elapsed 
since the initiation of an mTOR inhibitor to the first VTE episode was 2.2 years (IQR, 0.3–3.1 years). At 
the time of VTE, median serum levels of mTOR inhibitors were 5.1 ng/ml (IQR, 3.7–6.1 ng/ml) in 
patients who were taking everolimus and 6.3 ng/ml (IQR, 4.2–9.1 ng/ml) in patients who were taking 
sirolimus. 
Treatment 
Among 54 patients with a first VTE episode, 4 (7.4%) died within the first 24 hours after clinical 
presentation. Autopsy confirmed PE as a major contributor cause of death in all of these patients. The 
remaining 50 patients were treated with different anti-coagulant strategies. Upon diagnosis, low-
molecular weight heparin was initiated in 26 patients (52%) and intravenous heparin in 24 (48%). In 
addition, 1 patient received intravenous thrombolysis, 1 patient underwent inferior vena cava filter 
implantation, and 1 patient underwent venous embolectomy. 
 
After the early post-VTE phase, 47 patients (94%) received oral acenocoumarol (Sintrom, Novartis 
Pharma, Basel, Switzerland), with an international normalized ratio (INR) therapeutic target of 2 to 3. No 
patient was treated with rivaroxaban or apixaban. Oral anti-coagulation was discontinued in 29 patients 
(58%), 3 of them due to major bleeding, and was maintained permanently until the end of follow-up in 21 
patients (42%). The median duration of anti-coagulant therapy in the entire population was 515 days 
(IQR, 192–1,448 days). The median duration of anti-coagulation in patients who discontinued this 
treatment was 252 days (IQR, 101–510 days). 
Recurrence 
Recurrence of VTE was observed in 8 patients (16.3%), 1 of whom died as a consequence of the 
relapsing episode (PE). Median time elapsed from the first VTE episode to VTE recurrence was 1.7 years 
(IQR, 0.6–8 years). The overall incidence rate of VTE recurrence after a first VTE episode was 30.5 (95% 
CI, 13.2–60.2) episodes per 1,000 patient-years. 
 
Only 2 patients (4%) experienced a VTE recurrence while on anti-coagulant therapy. The VTE 
recurrence in 1 patient appeared during a transient discontinuation of the treatment due to a planned 
invasive procedure. Incidence rate of VTE recurrence per 1,000 patient-years was 19.2 (95% CI, 2.3–
69.5) episodes in patients receiving anti-coagulation and 50.8 (95% CI, 18.7–110.7) episodes after the 
permanent discontinuation of this therapy. 
Discussion 
This study systematically assessed the incidence, recurrence, and predisposing factors of VTE after 
HT. In our single-center cohort of 635 consecutive HT recipients with a median follow-up of more than 8 
years, we observed a VTE cumulative incidence of 8.5% and a VTE incidence rate of 12.7 episodes per 
1,000 patient-years. The risk of VTE was higher during the first 12 months after HT (45.1 episodes per 
1,000 patient-years) and decreased significantly beyond this time (8.7 episodes per 1,000 patient-years). 
Even if VTE episodes that occurred within the first post-transplant year are not taken into account, these 
data reflect more than a 6-fold increase of VTE incidence compared with that reported for individuals 




 After a first VTE episode, the risk of recurrence was high (30.5 episodes 
per 1,000 patient-years), especially after the discontinuation of anti-coagulant therapy (50.8 episodes per 
1,000 patient-years). By means of multivariable models, chronic renal dysfunction, older age, obesity, and 
an emergency transplantation were identified as independent risk factors for early (<1 year) post-
transplant VTE, whereas the use of mTOR inhibitors was identified as an independent risk factor for the 
occurrence of late (>1 year) post-transplant VTE. 
 
Solid-organ transplant recipients are exposed to a higher risk of VTE than patients from the general 
population. With variable follow-up duration among studies, the reported cumulative incidence of VTE 
varied between 4.5% and 9.1% in kidney transplant recipients,
3-6
 between 8.6% and 29% in lung 
transplant recipients,
7-10
 and between 0.4% and 4.6% in liver transplant recipients.
11-13
 In a single-center 
observational study
14
 including 67 HT recipients treated with a sirolimus-based immunosuppressive 
regimen and 134 HT matched controls, the cumulative incidence of VTE during a mean follow-up of 
more than 3 years was 8.5%. Hypercoagulability secondary to chronic immunosuppressive therapy is 




Almost 40% of all VTE episodes in our series occurred within the first 12 months after HT, most of 
them during the early post-operative period. Previous studies
3,8
 have already shown that the risk of VTE 
is high at early stages after solid-organ transplantation, favored by surgical injury and immobilization. In 
our study, obesity, older age, and chronic renal dysfunction were associated with an increased incidence 
of early post-transplant VTE. These are well-characterized pre-disposing factors for VTE in other solid-
organ recipients
3,9,13
 and also in the general population.
22-24
 Emergency transplantation was also identified 
as a strong risk factor for early post-transplant VTE. The pre-transplant clinical condition in patients 
undergoing this type of procedure is usually severely impaired and requires invasive therapies, such as 
mechanical circulatory support or mechanical ventilation, and they are exposed to an increased risk of 
post-transplant complications such as primary graft failure, nosocomial infection, and critical illness 
polyneuropathy. This clinical picture frequently results in prolonged stays in the intensive care unit and in 
late postoperative mobilization, which increase the risk of VTE. 
  
The use of mTOR inhibitors (sirolimus and everolimus) was the only variable that showed a 
statistically significant association with the occurrence of VTE after the first post-transplant year in our 
cohort. A few recent studies have suggested that solid organ recipients receiving mTOR inhibitors might 
be exposed to an increased risk of thromboembolic events, raising a significant concern about the safety 
of this group of drugs. A sub-analysis of a randomized clinical trial
10
 found that lung transplant recipients 
treated with a sirolimus-based regimen presented a statistically significant higher cumulative incidence of 
VTE during a 3-year follow-up period of 17.2% vs 3.2% in others treated with an azathioprine-based 
regimen. In an observational study,
14
 HT recipients on a sirolimus-based regimen presented a higher 
cumulative incidence of VTE than matched controls not receiving mTOR inhibitors (12% vs 7%), but this 
difference was no longer statistically significant after multivariable adjustment. A study in renal 
transplant recipients
25
 revealed that patients treated with everolimus had higher serum levels of several 
pro-coagulant factors compared with patients treated with other immunosuppressive regimens, resulting 
in increased endothelial activation, enhanced thrombin formation, and impaired fibrinolysis. However, the 
evidence that supports a potential association between mTOR inhibitors and an increased risk of VTE 
events is still weak and might be confounded by a high prevalence of comorbid conditions such as 
chronic renal failure, dyslipidemia, or malignancy in patients taking these kinds of drugs. Larger 
prospective multicenter studies are therefore warranted to clarify this question. 
 
Another key point of our investigation is the significant risk of VTE recurrence observed in HT 
recipients who experienced a first VTE episode, consistently with previously described in renal transplant 
recipients.
4-5
 Of note, most of the recurrent VTE episodes occurred in patients in whom oral anti-
coagulation had already been stopped. In view of these findings, it might be reasonable to maintain long-
term oral anti-coagulation in HT recipients who experience a first VTE episode, especially when any 
other permanent risk factor is present, such as obesity, malignancy, renal dysfunction, mTOR inhibitor 
therapy, and provided that the estimated bleeding risk is not excessively high. 
 
Our study has a few limitations. First, we conducted a retrospective analysis, so results may be 
conditioned by selection, information, and confusion biases inherent to this type of investigation. The 
relatively low number of VTE episodes after the first post-transplant year may have prevented us from 
detecting a statistically significant association between certain variables and the study outcome, as might 
be the case with post-transplant malignancy. Also, the association between the use of mTOR inhibitors 
and VTE must be interpreted with caution, given that the study design did not allow us to establish a 
conclusive cause-and-effect correlation between both variables. Data on international normalized ratios 
were not collected, so we are not able to extract reliable conclusions about the efficacy of anti-coagulant 
therapy in the HT population. Finally, the limited setting of the investigation, which was conducted in a 
single institution, implies that its external validity is not warranted. 
 
In conclusion, VTE is a relatively frequent complication in HT recipients, especially during the first 
post-transplant year. In our study, classic thromboembolic risk factors, such as older age, obesity, and 
renal dysfunction, were associated with increased risk of early (<1 year) post-transplant VTE, whereas the 
use of mTOR inhibitors was a major predisposing factor for late (>1 year) post-transplant VTE. 
Interestingly, the risk of VTE recurrence after a first VTE episode was high, so our opinion is that long-
term oral anti-coagulation should be maintained in these patients, especially if other risk factors are 
present and provided that the bleeding risk is not excessive. Further investigation is required to clarify the 
underlying mechanisms and the optimal clinical management of venous thromboembolic complications in 
this specific population. 
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